Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer

Key Points

• Antitumor immune response improves with LTX-315 treatment in liver cancer patients, indicating strong potential.
• LTX-315 targets the PD-L1 pathway, enhancing the efficacy of the nanosecond pulse electric field.
• Assessment using nanosecond pulse electric field facilitates improved immune activation against liver cancer.
• Implications highlight that targeting PD-L1 with LTX-315 may enable better liver cancer therapies in clinical settings.